SCHEMBL4680215

SCHEMBL4680215

CCCCCOC(=O)Nc1nc(CCl)cs1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.67
MAPK1 P28482 1/20 0.67
SMN1; SMN2 Q16637 5/20 0.58
KMT2A Q03164 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 2/20 0.50
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
PDE5A O76074 1/20 0.47
CYP1A2 P05177 1/20 0.47
NFKB1 P19838 1/20 0.47
CYP2C19 P33261 1/20 0.47
STAT1 P42224 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
CSNK2A2 P19784 3/20 0.46
CSNK2A1 P68400 3/20 0.46
GAA P10253 1/20 0.45
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91861 0.90 TSHR (0.70) TSHRMAPK1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL91407 0.88 TSHR (0.68) TSHRMAPK1SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL4874907 0.85 KMT2A (0.66) TSHRMAPK1SMN1; SMN2KMT2AALDH1A1
SCHEMBL4685246 0.80 PDE5A (0.70) TSHRMAPK1SMN1; SMN2KMT2AALDH1A1
SCHEMBL91587 0.80 MAPK1 (0.63) TSHRMAPK1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL77077 0.80 MAPK1 (0.57) TSHRMAPK1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL9836846 0.79 PDE5A (0.64) TSHRMAPK1SMN1; SMN2KMT2AALDH1A1
SCHEMBL77674 0.79 MAPK1 (0.56) TSHRMAPK1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL356279 0.76 SMN1; SMN2 (0.64) TSHRMAPK1SMN1; SMN2KMT2AALDH1A1
SCHEMBL5503951 0.75 TSHR (0.61) TSHRMAPK1SMN1; SMN2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1426371-B1 TETRAZOYL OXIME DERIVATIVES AND AGROCHEMICALS CONTAINING THE SAME AS THE ACTIVE INGREDIENT NIPPON SODA CO (JP) 2008-12-03 EP disclosed
US-20070105926-A1 Tetrazoyloxime derivative and agricultural chemical containing the same as active ingredient NIPPON SODA CO., LTD (JP) 2007-05-10 US disclosed
US-7183299-B2 Tetrazoyl oxime derivative and agricultural chemical containing the same as active ingredient NIPPON SODA CO., LTD. (JP) 2007-02-27 US disclosed
CN-1259318-C Tetrazoyl oxime derivative and agricultural chemical containing the same as active ingredient DAINIPPON INK & CHEMICALS (JP) 2006-06-14 CN disclosed
US-20050070439-A1 Tetrazoyl oxime derivative and agricultural chemical containing the same as active ingredient DAINIPPON INK AND CHEMICALS, INC. (JP) 2005-03-31 US disclosed
CN-1553907-A Tetrazoyl oxime derivative and agricultural chemical containing the same as active ingredient ���ձ���ī��ѧ��ҵ��ʽ���� 2004-12-08 CN disclosed
EP-1426371-A1 TETRAZOYL OXIME DERIVATIVE AND AGRICULTURAL CHEMICAL CONTAINING THE SAME AS ACTIVE INGREDIENT DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105926-A1 Tetrazoyloxime derivative and agricultural chemical containing the same as active ingredient PAOX, TH, CYP2E1 TSHR 1804/4885MAPK1 935/4885SMN1; SMN2 2940/4885
US-20050070439-A1 Tetrazoyl oxime derivative and agricultural chemical containing the same as active ingredient TH, CYP2E1, PAOX TSHR 1383/4885MAPK1 894/4885SMN1; SMN2 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.